NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/24/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization100.06 mln
Float40.37 mln
Earnings Date08/07/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
99
/ 100
Top performer
Debt / Equity
0.04
Debt-free
ROE
-81.80
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Entera Bio is an Israel-based company focused on turning injectable hormone and protein treatments into pills that patients can swallow. The company has several drugs in clinical testing, targeting conditions such as osteoporosis, obesity, and rare hormonal disorders. Its most advanced candidate is an oral version of teriparatide, a drug commonly used to treat bone loss, which has already completed a mid-stage clinical trial. Entera also works with partner companies to advance additional treatments through early-stage research and testing.